GI-MAP Stool Test: A Naturopathic Clinician's Guide to Interpretation

A clinician-facing guide to interpreting the GI-MAP stool test — covering DNA-based methodology, key marker panels (H. pylori, parasites, commensals, opportunistic bacteria, intestinal health markers), naturopathic treatment implications per finding, and when to retest.

This article is intended for health professionals and informed practitioners. It does not constitute individual medical advice. All findings from functional stool testing require clinical interpretation by a qualified practitioner.

The GI-MAP (Gastrointestinal Microbial Assay Plus) has become one of the most widely ordered functional stool tests in naturopathic and integrative clinical settings. Unlike older culture-based stool analysis, the GI-MAP uses quantitative polymerase chain reaction (qPCR) — a DNA-based detection method — to identify and quantify microbial targets with a precision that conventional stool culture cannot match.

Understanding how to read a GI-MAP report, what the quantitative values actually mean clinically, and how to translate those findings into a coherent treatment strategy is an essential competency for any naturopath or integrative practitioner ordering the test. This guide walks through the full panel, section by section, with clinical interpretation frameworks and naturopathic treatment implications for common findings.

DNA-Based Testing vs. Culture-Based Stool Analysis

Before interpreting results, it is worth understanding why the methodology matters.

Culture-Based Analysis: Limitations

Traditional stool culture requires that organisms survive transit, collection, and laboratory conditions in a viable, culturable state. Many important gut pathogens and commensal organisms are either strictly anaerobic, present in low abundance, or simply difficult to culture under standard conditions. Culture methods have been estimated to detect fewer than 1% of the microbial taxa present in the gut. This means conventional stool culture routinely misses clinically relevant organisms — including H. pylori (which requires specialised culture conditions), many parasites, and most commensal anaerobes.

qPCR: What It Detects and How

qPCR amplifies and quantifies specific DNA sequences. The GI-MAP targets genetic material from organisms even when they are non-viable, fragmented, or present in low numbers. Key advantages for clinical use:

Sensitivity: Detects organisms at much lower concentrations than culture
Specificity: Targets species-specific or genus-specific DNA sequences — reduces false positives from cross-reactive organisms
Quantification: Results are expressed in DNA copies per gram of stool (reported as log values), allowing comparison over time and against reference ranges
Anaerobic coverage: Captures organisms that would not survive standard culture conditions

Understanding Log Values

GI-MAP results are expressed as log₁₀ values of DNA copies per gram of stool. This is important for interpreting apparent small numerical differences:

A result of 4.0 = 10,000 copies/g
A result of 5.0 = 100,000 copies/g
A result of 6.0 = 1,000,000 copies/g

A single-point increase on the log scale represents a tenfold increase in organism load. This is why a shift from 4.5 to 5.5 represents a clinically meaningful change, not a marginal one.

Section 1: H. pylori and Virulence Factors

H. pylori Detection

Helicobacter pylori is detected as a primary result, with presence or absence reported. When positive, the GI-MAP uniquely also reports multiple virulence factor genes that significantly affect clinical management.

Virulence factors tested:

| Virulence Factor | Clinical Significance | |---|---| | CagA (cytotoxin-associated gene A) | Most clinically significant; strongly associated with peptic ulcer disease, atrophic gastritis, and gastric adenocarcinoma risk | | VacA (vacuolating cytotoxin A) | Induces vacuolation and apoptosis in gastric epithelium; severity depends on allele type (s1/s2, m1/m2) | | DupA (duodenal ulcer-promoting gene A) | Associated with duodenal ulcer but not necessarily gastric cancer | | OipA (outer inflammatory protein A) | Promotes mucosal inflammation | | BabA (blood group antigen binding adhesin) | Mediates adhesion to gastric epithelium | | VirB2 | Part of the type IV secretion system for CagA injection |

Clinical Interpretation by Virulence Profile

H. pylori positive, virulence factors negative: Lower clinical urgency. Many carriers with no virulence factors have asymptomatic colonisation. Naturopathic approach: support gastric mucosal integrity, address known H. pylori lifestyle cofactors (acid suppressor use, smoking), monitor with symptom correlation.

H. pylori positive, CagA and/or VacA positive: Higher clinical urgency. These patients warrant strong consideration of referral for conventional eradication therapy (triple or quadruple antibiotic protocol). Naturopathic adjuncts — mastic gum (1,000 mg twice daily), bismuth-containing preparations, and lactoferrin — have supporting evidence as add-ons but should not delay necessary medical treatment in high-virulence cases.

Naturopathic adjuncts with evidence for H. pylori:

Mastic gum (Pistacia lentiscus): demonstrated bacteriostatic and bactericidal effects in clinical studies
Lactoferrin: impairs H. pylori iron acquisition; RCTs support it as adjunct to antibiotic eradication protocols
Sulforaphane (from broccoli sprout extract): inhibits H. pylori growth in vitro; pilot clinical data supportive
Deglycyrrhizinated liquorice (DGL): supports mucosal healing and reduces adhesion

Section 2: Gastrointestinal Pathogens

This panel covers bacterial, viral, and parasitic pathogens that cause acute and sometimes chronic gastrointestinal disease.

Bacterial Pathogens

Key organisms tested include Campylobacter spp., Clostridium difficile (toxin A and B genes), Escherichia coli O157, enteroaggregative E. coli (EAEC), enteroinvasive E. coli (EIEC), enteropathogenic E. coli (EPEC), enterotoxigenic E. coli (ETEC), Shiga toxin-producing E. coli (STEC), Salmonella spp., Shigella/EIEC, Vibrio cholerae, and Yersinia enterocolitica.

Clinical note on C. difficile: The GI-MAP reports C. difficile toxin genes (A and B). A positive result in a patient without recent antibiotic exposure or diarrhoea requires careful clinical correlation — low-level C. difficile colonisation without toxin production is possible and may not be clinically active. Treatment decisions should incorporate clinical context, not the result in isolation.

Parasitic Pathogens

Cryptosporidium spp.
Entamoeba histolytica
Giardia duodenalis

Giardia and Cryptosporidium are among the more commonly detected positives in naturopathic clinical practice, particularly in patients with travel history, compromised secretory IgA, or well water exposure.

Naturopathic approach to confirmed Giardia: Berberine-containing herbs (Berberis vulgaris, Hydrastis canadensis) have clinical evidence and in vitro activity against Giardia. Oregano oil (carvacrol and thymol) and wormwood (Artemisia absinthium) are also used in practice. However, confirmed Giardia in symptomatic patients typically warrants referral for metronidazole or tinidazole — naturopathic approaches may be used as adjuncts or for refractory/recurrent cases.

Viral Pathogens

Adenovirus 40/41, norovirus GI/GII, and rotavirus A are included — primarily relevant in acute gastroenteritis presentations. Positive findings in chronic patients may suggest ongoing post-viral gut motility disturbance or persistent immune activation rather than active acute infection.

Section 3: Opportunistic Bacteria

This section is frequently misinterpreted. Opportunistic bacteria are organisms that are present in the gut at low levels in healthy individuals but can expand and cause symptoms when gut ecology is disturbed.

Key opportunistic organisms on the GI-MAP:

Bacillus cereus
Enterococcus faecalis / faecium
Klebsiella pneumoniae
Morganella morganii
Pseudomonas aeruginosa
Staphylococcus aureus
Streptococcus spp.
Proteus mirabilis
Prevotella copri (elevated in context of inflammatory conditions)

Interpretation Principles for Opportunistic Bacteria

Context is essential. A mildly elevated opportunistic organism in an otherwise well patient with robust secretory IgA and healthy keystone commensals is a very different clinical picture from the same finding in a patient with depleted commensals, low sIgA, and active gastrointestinal symptoms.

The primary naturopathic question is: what are the conditions that permitted this organism to expand? This points treatment upstream — toward rebuilding commensal populations, supporting mucosal immunity, and addressing dietary substrates that fuel the opportunist (often fermentable fibres that poorly-digested proteins feed into pathogenic niches).

Prevotella copri warrants special mention. Its association with rheumatoid arthritis and inflammatory joint conditions is an area of active research. Elevated P. copri in a patient with inflammatory arthritis or autoimmune presentation adds a clinically relevant gut-immune axis dimension to the case.

Section 4: Normal Bacterial Flora (Keystone Commensals)

This is the section most practitioners under-read. The keystone commensals — also called beneficial bacteria — are not incidental background noise. Their abundance and balance have direct implications for mucosal immune function, short-chain fatty acid production, intestinal motility, and resistance to pathogen colonisation.

Key Commensals and Their Clinical Roles

Lactobacillus spp. Produce lactic acid and bacteriocins that inhibit pathogen adhesion; support tight junction integrity; modulate mucosal IgA secretion. Depleted Lactobacillus is common after antibiotic courses and in patients with high sugar diets or chronic stress.

Bifidobacterium spp. Major producers of short-chain fatty acids (SCFAs), particularly acetate; ferment dietary fibre; support colonocyte energy metabolism; reduce intestinal pH. Depletion correlates with increased intestinal permeability and immune dysregulation.

Faecalibacterium prausnitzii Arguably the most clinically significant individual commensal on the GI-MAP. F. prausnitzii is the primary gut producer of butyrate — the preferred energy substrate for colonocytes and a critical anti-inflammatory signal in the intestinal mucosa. Reduced F. prausnitzii is consistently found in active IBD, particularly Crohn's disease, and in irritable bowel syndrome. It is highly sensitive to oxygen exposure, reduced by antibiotics, and poorly restored by standard probiotic supplementation.

Naturopathic strategies to support F. prausnitzii:

High inulin-type fructan foods (Jerusalem artichoke, chicory root, leek, garlic, onion)
Resistant starch (green banana flour, cooled cooked potato, legumes)
Avoidance of long-chain PUFA excess (which reduces butyrate production)
Reducing dietary emulsifiers (polysorbate 80, carboxymethylcellulose) which deplete F. prausnitzii populations in animal and emerging human data

Akkermansia muciniphila A mucolytic bacterium that maintains mucus layer thickness and tight junction integrity. Akkermansia depletion correlates with leaky gut, metabolic dysfunction, and obesity. Pasteurised Akkermansia supplementation is now commercially available and has Phase 1/2 human trial data supporting its safety and metabolic benefits. Foods that support Akkermansia: polyphenol-rich foods (pomegranate, cranberry, green tea), omega-3 fatty acids.

Roseburia intestinalis, Prevotella (in healthy context), Clostridiales spp. Additional butyrate producers assessed in the commensal panel. Their depletion, alongside F. prausnitzii, signals a broadly dysbiotic microbiome with reduced SCFA production capacity.

Section 5: Intestinal Health Markers

This panel covers non-microbial markers that assess mucosal immune function, intestinal barrier integrity, inflammation, and digestive efficiency. These markers often provide the most actionable clinical information.

Secretory IgA (sIgA)

Secretory IgA is the primary mucosal antibody — the first line of adaptive immune defence at mucosal surfaces. In the gut, sIgA coats bacteria and food antigens, preventing pathogen adhesion and antigen penetration through the epithelium.

Low sIgA is one of the most clinically significant findings on a GI-MAP report. It indicates compromised mucosal immune function and is associated with:

Increased susceptibility to intestinal infections and pathogen colonisation
Higher rates of food sensitivity (antigens breaching the mucosa at higher rates)
Poor response to probiotic interventions (probiotics cannot colonise well without adequate mucosal immune context)
Chronic stress and HPA axis dysregulation (cortisol directly suppresses sIgA secretion)

Naturopathic support for low sIgA:

Stress reduction and HPA axis support — ashwagandha's evidence for cortisol modulation is directly relevant here, as chronic cortisol elevation is a primary driver of sIgA suppression
Colostrum supplementation (bovine): supports sIgA production and mucosal repair
Saccharomyces boulardii: specifically stimulates sIgA secretion — well-documented in RCTs
Zinc (15–25 mg elemental zinc as citrate or picolinate): cofactor for sIgA-producing plasma cells
Vitamin A (as retinol): essential for gut-associated lymphoid tissue (GALT) function and sIgA class switching

High sIgA indicates active mucosal immune stimulation — the immune system is mounting a response to something. This may reflect active infection (cross-reference with pathogen panel), ongoing food antigen exposure in a permeable gut, or chronic low-grade dysbiosis. High sIgA is not necessarily pathological — it may be an appropriate immune response — but the trigger should be identified.

Zonulin

Zonulin is a protein that regulates tight junction permeability between intestinal epithelial cells. When elevated, it indicates that tight junctions are being opened — the mechanism underlying increased intestinal permeability ("leaky gut").

Clinical drivers of elevated zonulin:

Gluten (gliadin activates zonulin release via CXCR3 receptor in susceptible individuals)
Giardia infection
SIBO (small intestinal bacterial overgrowth)
Dysbiosis (LPS from gram-negative bacteria activates zonulin release)
Psychological stress
NSAIDs (direct tight junction damage)

Naturopathic approach to elevated zonulin:

Identify and address the trigger (gluten trial, treat dysbiosis/parasites if present)
Glutamine (5–10 g/day): preferred enterocyte fuel, supports tight junction protein synthesis
Zinc carnosine: specific evidence for reducing gut permeability in clinical trials
Deglycyrrhizinated liquorice (DGL) and slippery elm: support mucus layer as physical barrier
Consider the role of methylation status in tight junction regulation — impaired methylation affects DNA methylation of tight junction genes; the MTHFR methylation clinical guide covers the biochemistry of methylation-gut interactions

Calprotectin

Calprotectin is a calcium-binding protein released from activated neutrophils. Its presence in stool is a direct measure of intestinal mucosal inflammation — and a well-validated one. Calprotectin is the same marker used in conventional gastroenterology to differentiate IBD from IBS and to monitor IBD disease activity.

GI-MAP calprotectin reference ranges (Diagnostic Solutions Laboratory):

Normal: <120 µg/g
Borderline: 120–200 µg/g (requires clinical correlation)
Elevated: >200 µg/g (indicates significant mucosal inflammation)
High concern: >500 µg/g (merits urgent gastroenterology referral)

Clinical action on elevated calprotectin: Elevated calprotectin in a patient without known IBD warrants referral for colonoscopy to rule out IBD, colon polyps, or colorectal malignancy before naturopathic treatment is initiated. This is not a marker to manage conservatively without appropriate medical workup at high levels.

Where calprotectin is borderline or mildly elevated with a clear dysbiosis picture (and after ruling out organic pathology), naturopathic anti-inflammatory support is appropriate: omega-3 fatty acids (EPA/DHA 3–4 g/day), curcumin (with phospholipid delivery systems for bioavailability), butyrate (as sodium or tributyrin), and addressing the underlying dysbiosis driving the inflammatory signal.

Lysozyme

Lysozyme is an antimicrobial enzyme produced by Paneth cells and macrophages in the intestinal mucosa. Elevated lysozyme on GI-MAP suggests active mucosal immune activation — typically indicating infection, significant dysbiosis, or mucosal inflammation. Interpretation should be in conjunction with calprotectin and sIgA.

Lactoferrin

Lactoferrin is an iron-binding glycoprotein with broad antimicrobial and anti-inflammatory activity. On GI-MAP it serves as an additional marker of mucosal inflammation and immune activation, complementary to calprotectin. Stool lactoferrin may also be elevated in bacterial gastroenteritis.

Anti-Gliadin IgA

Secretory IgA specific to gliadin (a gluten protein fraction) detected in stool. Elevated anti-gliadin sIgA indicates active mucosal immune reactivity to gluten, regardless of serum coeliac antibody status. This finding supports consideration of a gluten elimination trial even in the absence of confirmed coeliac disease — though clinical correlation and symptom response to elimination remain the gold standard.

Section 6: Digestive Function Markers

Pancreatic Elastase-1

Pancreatic elastase-1 (PE-1) is an enzyme produced exclusively by the pancreas and is largely resistant to degradation during intestinal transit. Stool PE-1 level is therefore a reliable indirect measure of exocrine pancreatic function.

Reference ranges:

Normal: >200 µg/g
Mild/moderate exocrine pancreatic insufficiency (EPI): 100–200 µg/g
Severe EPI: <100 µg/g

Clinical interpretation: Low PE-1 in the context of bloating, steatorrhoea, floating/foul-smelling stools, and weight loss (or difficulty gaining weight) confirms exocrine pancreatic insufficiency. Causes range from chronic pancreatitis and pancreatic duct obstruction to prolonged proton pump inhibitor use and coeliac disease. Confirmed severe EPI warrants gastroenterology referral for formal workup and consideration of pancreatic enzyme replacement therapy (PERT).

Naturopathic support for mild-moderate EPI: pancreatic enzyme supplementation (plant-sourced or porcine), reduction of dietary fat load until enzyme support is established, addressing any underlying gut inflammation that may affect enzyme secretion, and identifying root causes.

Section 7: Beta-Glucuronidase

Beta-glucuronidase is a bacterial enzyme produced primarily by Bacteroidetes, Firmicutes, and Ruminococcaceae. Its clinical significance relates to oestrogen recycling and detoxification.

In the liver, oestrogens are conjugated with glucuronic acid (phase II detoxification) for excretion in bile. Beta-glucuronidase produced by gut bacteria can cleave this conjugate in the intestine, releasing free, unconjugated oestrogen that is reabsorbed — effectively recirculating oestrogens and increasing oestrogen exposure.

Elevated beta-glucuronidase is associated with:

Oestrogen dominance presentations
Increased circulating oestradiol levels despite adequate hepatic detoxification
Elevated risk in oestrogen-sensitive conditions

Naturopathic approach:

Calcium D-glucarate (450–900 mg twice daily): inhibits beta-glucuronidase activity, reducing intestinal oestrogen deconjugation
Increase dietary glucarate-containing foods: broccoli, Brussels sprouts, apples, grapefruit
Ensure adequate dietary fibre (soluble and insoluble) to support oestrogen-bound bile excretion
Address the dysbiosis driving excess beta-glucuronidase production — high-fat, low-fibre diet, and dysbiotic microbiome are primary drivers

Naturopathic Treatment Frameworks by GI-MAP Finding

Dysbiosis Without Pathogen Positives

This is the most common clinical GI-MAP scenario: depleted commensals, elevated opportunistic bacteria, normal pathogens, with intestinal health markers showing low sIgA and/or mildly elevated zonulin.

Phase approach:

Remove — antimicrobial herbs targeting opportunistic organisms (berberine, oregano oil, garlic allicin, Andrographis); address dietary drivers (reduce refined carbohydrates, emulsifiers)
Repair — mucosa support (glutamine, zinc carnosine, DGL, aloe vera inner leaf); restore tight junction integrity
Replace — digestive enzymes if PE-1 is low; bile support if fat digestion appears impaired
Reinoculate — targeted probiotics (Lactobacillus and Bifidobacterium strains for mucosal support, S. boulardii for sIgA); dietary prebiotic substrate (inulin-type fructans, resistant starch)
Rebalance — HPA axis support for chronic stress-driven sIgA suppression; adaptogenic support with Rhodiola rosea has clinical evidence for HPA axis modulation and is relevant in stress-driven dysbiosis cases; consider CoQ10 if mitochondrial/enterocyte energy production appears compromised — the CoQ10 and ubiquinol clinical guide covers tissue-level ubiquinol and enterocyte energy demand

H. pylori Positive with High-Virulence Factors

Refer for medical eradication therapy. Naturopathic role: support mucosal healing post-eradication, restore depleted microbiome (antibiotics for H. pylori significantly disrupt commensal populations), and address nutritional deficiencies secondary to hypochlorhydria (B12, iron, zinc).

Elevated Calprotectin

Refer for colonoscopy to rule out IBD/pathology. Post-ruling-out: anti-inflammatory protocol as described above.

Parasite Positive (Giardia/Cryptosporidium)

Refer for or co-manage with antiparasitic treatment. Naturopathic adjuncts and post-treatment gut repair are the core contribution.

BPC-157 and Gut Research: An Emerging Context

For practitioners who follow peptide research, BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide that has been studied extensively in animal models for its effects on gut mucosal healing, motility regulation, and intestinal barrier function. Research models have investigated BPC-157 in contexts including inflammatory bowel disease, short bowel syndrome, and intestinal anastomosis repair. For practitioners wanting to understand the current research landscape around gut-targeted peptide compounds, BPC-157 gut research context is available at ozpeps.is — noting that this remains preclinical research territory and any clinical application requires specialist input.

When to Retest

Retesting timing depends on clinical presentation and treatment intensity:

Dysbiosis treatment (herbal antimicrobials + probiotic reinoculation): Retest at 3–4 months post-initiation
H. pylori post-eradication: Retest at minimum 4 weeks post-antibiotic cessation (early retesting produces false negatives due to bacterial suppression without clearance)
Parasite treatment: Retest at 4–6 weeks post-treatment completion
Monitoring IBD (elevated calprotectin): As directed by gastroenterology; may be repeated 3-monthly during active disease management
Routine wellness monitoring: Annual or biannual retesting is increasingly used in proactive health maintenance practices

Frequently Asked Questions

Q: How should I prepare my patient for GI-MAP collection?

The GI-MAP requires a single stool sample collected at home and returned to the laboratory within specified timeframes. Patients should avoid antibiotics for at least 2–4 weeks prior (ideally 4 weeks); herbal antimicrobials should ideally also be paused for 2 weeks prior, as berberine and oregano oil can suppress microbial DNA loads and produce false-negative readings. Proton pump inhibitors affect the gastric microenvironment and their cessation for 2 weeks prior is ideal (confirm this is safe with the prescribing physician before advising). Probiotics do not significantly interfere with results in most cases and do not need to be stopped.

Q: Can GI-MAP results diagnose IBD?

No. The GI-MAP calprotectin can flag significant mucosal inflammation consistent with IBD-level activity, but it cannot diagnose IBD — which requires colonoscopy with biopsy. A markedly elevated calprotectin (>500 µg/g) in a patient with new or worsening gastrointestinal symptoms warrants urgent gastroenterology referral, not empirical naturopathic treatment while awaiting a routine retest.

Q: Are the reference ranges on the GI-MAP absolute?

GI-MAP reference ranges represent optimal ranges based on Diagnostic Solutions Laboratory's clinical database, not validated population norms from large epidemiological studies. Results should always be interpreted in clinical context — a marginally low Lactobacillus in an otherwise asymptomatic patient with high F. prausnitzii and normal intestinal health markers does not necessarily indicate pathology requiring intervention.

Q: How do I explain GI-MAP results to patients who have never heard of functional stool testing?

A useful framing: the GI-MAP is a DNA-level inventory of your gut — it identifies what microbes are present, whether any pathogens are detected, how your gut immune system is functioning, and whether your intestinal lining is inflamed or permeable. It gives us a more complete picture than a standard stool culture because it detects organisms based on their genetic fingerprint rather than whether they can survive in a laboratory dish.

Q: Is GI-MAP covered by Medicare in Australia?

No. GI-MAP is a private functional test, not a Medicare-rebatable item. As of 2026, patients pay privately — costs typically range from $350 to $500 AUD through Australian-based test distributors. Some private health insurers reimburse a portion under extras cover depending on the policy.

Q: When is GI-MAP not the right test?

The GI-MAP is best suited to patients with chronic gastrointestinal symptoms, unexplained immune dysfunction, autoimmune conditions with a suspected gut axis, or as part of a broader integrative assessment. It is not the first-line investigation for acute gastroenteritis (standard pathology panels suffice), for coeliac disease diagnosis (serology and biopsy remain the standard), or for colorectal cancer screening (faecal occult blood testing and colonoscopy are the appropriate modalities).

References: Caporaso JG et al. Moving pictures of the human microbiome. Genome Biology. 2011;12(5):R50. | Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56–64. | Arumugam M et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–180. | Plovier H et al. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium improves metabolism in obese and diabetic mice. Nature Medicine. 2017;23(1):107–113. | Guarino A et al. ESPGHAN/ESPID guidelines for the management of acute gastroenteritis. JPGN. 2014;59(1):132–152. | Lippi G, Plebani M. Fecal calprotectin. Clinica Chimica Acta. 2012;413(19–20):1543–1547.

This article is intended for educational purposes and professional practice reference. It does not constitute individual medical advice. Clinical decisions should be made in the context of a full patient assessment by a qualified practitioner.